Related Experiment Videos
[High-dose thiotepa chemotherapy in children]
D G Izhogin1, V K Boiarshinov, I S Dolgonolov
1N.N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow.
Voprosy Onkologii
|January 9, 2001
Summary
High-dose thiotepa (800-900 mg/m2) chemotherapy caused severe toxicity and death. A reduced dose of 600 mg/m2 was found optimal for conditioning regimens, balancing antitumor effects with reduced fatal complications.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- High-dose chemotherapy regimens are used in cancer treatment.
- Thiotepa is an alkylating agent used in polychemotherapy.
- Evaluating optimal dosing is crucial for balancing efficacy and toxicity.
Purpose of the Study:
- To determine the optimal dose of thiotepa for conditioning regimens.
- To assess the toxicity and lethality associated with high-dose thiotepa.
- To evaluate the antitumor effect of thiotepa at different doses.
Main Methods:
- Retrospective analysis of patients receiving thiotepa-based polychemotherapy.
- Dose escalation and evaluation of toxicity and lethality.
- Assessment of antitumor response in relation to thiotepa dosage.
Main Results:
- High doses of thiotepa (800-900 mg/m2) were associated with significant toxicity and lethality.
- A dose of 600 mg/m2 demonstrated an optimal balance between antitumor activity and safety.
- The 600 mg/m2 dose did not result in fatal complications in double-conditioning regimens.
Conclusions:
- High-dose thiotepa (800-900 mg/m2) is poorly tolerated and associated with unacceptable lethality.
- Thiotepa at 600 mg/m2 is an effective and safer dose for double-conditioning regimens.
- Optimizing thiotepa dosage is critical for improving patient outcomes in conditioning regimens.